Persistent 18F-FDG brain PET fronto-temporal hypometabolism and cognitive symptoms two years after SARS-CoV-2 infection

Rossi, Stefania; Prodi, Elena; Morese, Rosalba; Paone, Gaetano; Ruberto, Teresa; Sacco, Leonardo

doi:10.3390/neurolint15030058

Back

Morese_2023_MDPI_Neurolint_Persistent 18F-FDG Brain

Journal article

Persistent 18F-FDG brain PET fronto-temporal hypometabolism and cognitive symptoms two years after SARS-CoV-2 infection : a case report

Rossi, Stefania Department of Neurology, Neuropsychology and Speech Therapy Unit, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
Prodi, Elena Department of Neuroradiology, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
Morese, Rosalba ORCID Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Facoltà di comunicazione, cultura e società, Università della Svizzera italiana, Svizzera
Paone, Gaetano Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Department of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
Ruberto, Teresa Department of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
Sacco, Leonardo Department of Neurology, Neuropsychology and Speech Therapy Unit, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland

2023

Published in:

Neurology International. - 2023, vol. 15, no. 3, p. 908–916

English At least 10% of patients experience persistent symptoms after SARS-CoV-2 infection, a condition referred to as post-acute COVID-19, post-acute sequelae of SARS-CoV-2 infection (PASC), long COVID, long-haul COVID, long-term effects of COVID, post-COVID-19 and chronic COVID. In this report, we describe a case of persistent cognitive deficits developed after SARS-CoV-2 infection in a 40-year-old woman with a family history of early-onset Alzheimer’s disease (EOAD) since her father was diagnosed with EOAD at the age of 50. We describe the clinical picture and workup, with special emphasis on the alterations of brain glucose metabolism evidenced by 18-fluoro-deoxy-glucose positron emission tomography (FDG-PET), which could be considered a useful marker of the presence and persistence of cognitive deficits.

Collections

Language